TCR² Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for patients suffering from solid tumors. The company is focused on the discovery and development of product candidates against novel and complex targets utilizing its proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells). The TRuC platform is designed to specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). For more information about TCR², please visit www.tcr2.com.
View Top Employees from TCR² Therapeutics Inc.| Website | http://www.tcr2.com |
| Ticker | TCRR |
| Revenue | $2 million |
| Employees | 136 (136 on RocketReach) |
| Founded | 2015 |
| Address | 100 Binney St Suite 710, Cambridge, Massachusetts 02142, US |
| Phone | (617) 949-5200 |
| Technologies |
JavaScript,
HTML,
PHP
+41 more
(view full list)
|
| Category | Organizations, Education, Biotechnology Research, Biotechnology, Cancer therapy, Science and Engineering, T cell biology, Health Care, Immunology, Life Science, Molecular biology, Medical, Pharmaceutical |
| Competitors | Eureka Therapeutics, Inc, Q Therapeutics, Syndax Pharmaceuticals, Tessa Therapeutics Ltd, Xintela AB |
| SIC | 87, 873 |
| NAICS | 5417, 54, 54171, 541711, 541 |
Looking for a particular TCR² Therapeutics Inc. employee's phone or email?
TCR² Therapeutics Inc. Questions
The TCR² Therapeutics Inc. annual revenue was $2 million in 2023.
Peter Olagunju is the COO of TCR² Therapeutics Inc..
136 people are employed at TCR² Therapeutics Inc..
TCR² Therapeutics Inc. is based in Cambridge, Massachusetts.
The NAICS codes for TCR² Therapeutics Inc. are [5417, 54, 54171, 541711, 541].
The SIC codes for TCR² Therapeutics Inc. are [87, 873].
Top TCR² Therapeutics Inc. Employees
-
25+
-
1
-
ViewAmy Lynch
Head of Operations and Human Resources at TCR² Therapeutics Inc.
Boston, Massachusetts, United States14
Related Companies
